Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review

Repurposing anticancer drugs for the management of COVID-19

Khalid El Bairi a,*, Dario Trapani b, Angelica Petrillo c,d, Cécile Le Page e, Hanaa Zbakh f, Bruno Daniele c, Rhizlane Belbaraka g, Giuseppe Curigliano b,h, Said Afqir a

a Department of Medical Oncology, Mohammed VI University Hospital, Oujda, Morocco
b European Institute of Oncology, IRCCS, Milan, Italy
c Medical Oncology Unit, Ospedale del Mare, Naples, Italy
d University of Study of Campania “L.Vanvitelli”, Naples, Italy
e Research Institute of McGill University Health Center (RI-MUHC), Montréal, QC, Canada
f Center of Marine Sciences, University of Algarve, Ed. 7, Campus of Gambelas, 8005-139, Faro, Portugal
g Department of Medical Oncology, “Bioscience et Sante” Research Laboratory, Faculty of Medicine, Cadi Ayad University, Marrakesh, Morocco
h University of Milan, Department of Oncology and Hematology, Milan, Italy

Received 18 June 2020; received in revised form 1 September 2020; accepted 2 September 2020
Available online 22 September 2020

KEYWORDS
COVID-19; SARS-CoV-2; Anticancer drugs; Repurposing

Abstract Since its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus is regarded as a global public health emergency. The existing therapeutic options for COVID-19 beyond the intensive supportive care are limited, with an undefined or modest efficacy reported so far. Drug repurposing represents an enthusiastic mechanism to use approved drugs outside the scope of their original indication and accelerate the discovery of new therapeutic options. With the emergence of COVID-19, drug repurposing has been largely applied for early clinical testing. In this review, we discuss some repurposed anticancer drugs for the treatment of COVID-19, which are under investigation in clinical trials or proposed for the clinical testing.

© 2020 Elsevier Ltd. All rights reserved.

* Corresponding author:
E-mail address: k.elbairi@ump.ac.ma (K. El Bairi).

https://doi.org/10.1016/j.ejca.2020.09.014
0959-8049/© 2020 Elsevier Ltd. All rights reserved.
1. Introduction

Novel coronavirus disease 2019 (COVID-19) has recently emerged as a potential life-threatening disease of public health interest, worldwide. Few pharmacotherapeutic options are available at the present time, and patients are experiencing adverse outcomes in the most severe presentations. The treatments used in the clinical care are mainly based on supportive measures and intensive care management for complicated cases [138]. Antiviral, antibiotic and antimalarial molecules have also been used to avoid severe outcomes as well as plasma therapy from recovered patients [12,19,75]. Despite the lack of strong evidence from clinical trials, several pharmacological treatments have been used in clinical practice and included in possible protocols based on preliminary findings of promising efficacy and a rationale against COVID-19, as suggested by recent systematic reviews [37,217]. However, if available, clinical trials remain the option of choice for patients with COVID-19, to enhance the data and progress in medical research. In this context, drug repurposing can be an attractive and promising approach for patients with COVID-19 in order to benefit from the safety and effectiveness of the molecules with proposed antiviral and/or immunomodulating properties [80,142]. Repurposed pipelines may have a significant impact, particularly in this critical time [44,78,161]. In this review article, we discuss the potential of a number of compounds licensed for cancer conditions that seem to have a rationale to target some pathogenic key mechanisms of COVID-19, under clinical investigation or proposed for clinical trials.

2. Drug repurposing as a substitute solution for emerging viral diseases of public health interest

The development of novel antiviral drugs requires long-term investigations in clinical trials. The advantage to repurpose drugs to validate off-label use is related to the known safety profile, though it may vary across the diseases, and consolidated data of pharmacodynamics, pharmacokinetics and efficacy in phase I–IV trials. Of interest, some host cellular targets interfering with the viral growth cycle, such as kinases, are broadly shared in the mechanisms of several viral infections and other conditions such as cancer, suggesting the possibility to translate knowledge across medical disciplines and disease models [56,156]. Therefore, pharmacologic approaches for targeting key pathogenic mechanisms, such as signalling pathways, constitute a promising tactic during outbreaks of emerging pathogens. A cost-effective drug repurposing has been previously used to combat intracellular pathogens as an urgent alternative during the occurrence of rapidly spreading and deadly infectious diseases: in fact, repurposed medicines may help reduce the investments in the earlier phases of drug development, with an immediate use in the specific setting of unmet need [66,118]. For instance, an accumulated experience on repurposed therapeutics during previous outbreaks caused by Ebola virus, dengue virus, severe acute respiratory syndrome coronavirus (SARS-CoV), Zika virus and Middle Eastern respiratory syndrome coronavirus (MERS-CoV) has led to the establishment of a rationale for synergistic drug combinations [9,20,32,47,213]. For example, the use of sofosbuvir plus ribavirin treatment, which is a combination of a nucleotide polymerase inhibitor and a synthetic antiviral nucleoside analogue approved for hepatitis C infection by the Food and Drug Administration (FDA) [187], has been repurposed for treating Zika virus infection. The two antiviral drugs were all tested in vivo for Zika disease and showed promising efficacy [22,57,160], thus prompting the clinical testing [16]. The antiprotozoal nitazoxanide developed by Romark Laboratories® is another important example [1,6]. Nitazoxanide is a thiazolide that triggers the host immune response by potentiating interferon release, interfering with post-translational stage of viral haemagglutinin and intracellular trafficking [157,191]. This drug showed potential properties with its broad-spectrum effects on other microbes encompassing Mycobacterium leprae [10], human norovirus [40] and Ebola virus [95]. Additionally, it has also been repurposed for influenza and is being tested in late-phase clinical trials (79) (for details, see: NCT03336619, NCT02612922, NCT01227421 and NCT01610245). Meanwhile, nitazoxanide is presently under investigation in two randomised clinical trials (NCT04343248 and NCT04341493) for COVID-19. Romark® is a phase III, randomised, double-blind, placebo-controlled trial evaluating the efficacy and safety of nitazoxanide (twice daily for 6 weeks) for post-exposure prophylaxis of COVID-19 in 300 patients (NCT04343248). A phase IV trial is already currently enrolling patients with COVID-19 and will compare nitazoxanide-hydroxychloroquine to hydroxychloroquine alone (NCT04341493). Hydroxychloroquine is an antimalarial drug that has been shown to interfere with the late-stage entry process of viruses based on cellular endocytic pathways. It is currently being investigated worldwide in more than 70 urgent clinical trials for COVID-19 (https://www.clinicaltrials.gov; accessed 14-04-2020). However, emerging evidence from a randomised and controlled phase III trial comparing hydroxychloroquine alone or with azithromycin versus standard care treatments for hospitalised patients with mild to moderate disease did not show clinically significant improvements after 15 d of treatment [25]. In the real world, similar results were obtained in an observational study with a larger cohort [68]. Notably, the latest meta-analysis with Bayesian examination of 29 studies including three randomised trials on this topic found evidence against...
the use of hydroxychloroquine alone or in combination with azithromycin in this setting [58].

3. Druggable targets in COVID-19-host signalling pathways

COVID-19 exhibits mild to moderate symptoms, which may progress into severe pneumonia, with lymphopenia, and an exhausted cytokine release syndrome [24]. The disease is caused by a novel strain of coronaviruses (SARS-CoV-2) that emerged in November–December 2019, probably naturally selected in an animal host before zoonotic transfer. However, SARS-CoV-2 has then crossed the animal species barriers and acquired the capacity of human-to-human infection, resulting in a rapid spread of COVID-19 at a pandemic proportion [83]. The SARS-CoV-2 is closely related to the previous strain SARS-CoV-1 that has caused the SARS epidemic in China during the period 2002–2004 [216]. SARS-CoV-2 is an enveloped, non-segmented and single-stranded RNA virus and belongs to the sarbecovirus subgenus of the Coronaviridae family [226]. The ultrastructure of SARS-CoV-2 is characterised by four key proteins, namely surface spike S glycoprotein, envelope protein E, membrane protein (M) and nucleocapsid protein (N) (Fig. 1A).

The mechanisms of infectivity and pathogenesis of this coronavirus are poorly known and seem to be similar to those of SARS-CoV and MERS-CoV [106] (Fig. 1B). The host cell entry of SARS-CoV-2 depends on angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) [86,205,207]. Human cells with rich cell-surface receptor ACE2, an important modulator involved in the blood pressure regulation, are susceptible to SARS-CoV-2 infection. According to the recently emerged evidence, the elucidated crystal structure of SARS-CoV-2 showed that its receptor-binding domain (RBD) has an enhanced affinity to bind to the human ACE2 [167]. The receptor-binding motif of the RBD mediates the contact with ACE2. Two virus-binding hotspots at the RBD–ACE interface are stabilised by several residue changes of amino-acids in SARS-CoV-2 as compared to the previous SARS-CoV-1 [167]. The entry into cells requires the protein S of the viral spike that binds to the receptor ACE2 facilitated by some host cell proteases, such as TMPRSS2 [71,173]. This phenomenon, based on protein S priming, enables fusion of viral and cellular membranes and escapes from antiviral humoral immune response [71,173]. This interaction seems to be targetable by inhibiting host proteases [86,169].

The marketed orally bioavailable camostat mesylate approved in Japan for the treatment of chronic pancreatitis and reflux oesophagitis after gastrectomy [101,123] demonstrated a significant inhibition of TMPRSS2 [86], suggesting a potential role to treat COVID-19. These effects were also observed in prostate...
cancer in which TMPRSS2 inhibition by camostat was associated with suppression of metastasis in vivo [109]. In addition, the use of soluble human ACE2 can inhibit early stage SARS-CoV-2 infections as revealed by a recent study including human organoids, by using the recombinant ACE2 as a decoy receptor [121]. Fig. 1B shows an overview about the potential targets for COVID-19 therapy.

After the fusion of viral and host cell membranes, the virus accesses by the endosomal pathway, facilitated by cathepsins (cysteine pH-dependent proteases) [18,144]. The virus dissembles and releases its nucleocapsid and RNA material into the host cell cytoplasm via caveolae- and clathrin-mediated endocytosis [215]. This pathway involves phosphatidylinositol binding clathrin assembly protein (PICALM), which is a cargo-selecting clathrin adaptor that drives membrane curvature during endocytosis [90,119]. The PICALM is a target of chloroquine that suppresses its expression [90,209], inhibiting in this way the clathrin-mediated endocytosis process. The genomic RNA of SARS-CoV-2 contains open reading frames, which are translated into two replicate polyproteins (pp1a and pp1b) [55]. Therefore, the replicase transcriptase complex (RTC) is generated by processing pp1a and pp1b to produce non-structural proteins (16 putative NSPs), which form RNA polymerase and helicase that have a central role in the transcription and replication of coronaviruses [26,195]. The RTC attaches to the endoplasmic reticulum (ER) membranes and produces double-membrane vesicles of the coronavirus. A part of the RTC undergoes other molecular changes for mRNA synthesis and splicing to generate the structural and accessory proteins of the virus. The glycoproteins of the envelope will reach the ER and Golgi apparatus in which they form with the nucleocapsid protein and the viral RNA the vesicle containing the virion [26]. After assembly via the ER–Golgi intermediate compartment, the release of the new virion-containing vesicles from the infected host cells is achieved by exocytosis [26,31]. An alternative cell surface non-endosomal route for coronavirus entry involves TMPRSS2 that cleaves the spike glycoprotein into S1 and S2 subunits [26]. This enables a fusion of the membranes of the coronavirus and target cell. Of note, TMPRSS2 is druggable by camostat that demonstrated efficacy as a single treatment in lung cell entry blockade of MERS-CoV [172].

The SARS-CoV-2 action on host immunity encompasses innate and adaptive immune response activation. Unfortunately, local and systemic uncontrolled inflammatory response as well as altered adaptive immune reactions can damage organ tissues [24]. Leukopenia and lymphopenia with reduced natural killer (NK) cells in addition to increased C-reactive protein can be seen in patients with severe COVID-19 [24,27]. A marked decrease of total CD8+ T cells and NK translates the early failure of antiviral immunity during SARS-CoV-2 infection [223]. Upregulation of the expression of CD94/NK group 2 member A (NKG2A) by these immune cells suggested a functional exhaustion of cytotoxic lymphocytes in the development of COVID-19 [223]. These features can result in high mortality and more severity of the disease [27,91,92,146].

Elevated serum levels of pro-inflammatory cytokines (known as cytokine release syndrome or cytokine storm), such as tumour-necrosis factor alpha (TNF-α) and interleukin 6 (IL-6), seem to cause multiple organ failure by damaging tissues, contributing to the poor outcomes in COVID-19 patients [14,24,70,117,159,210,218,220]. Notably, immunosuppression obtained with drugs targeting IL-6 axis such as tocilizumab (Actemra®, Genentech) or siltuximab (Sylvant®, Janssen) has been proposed [61,117,134,221]. Based on these assumptions, several phase III trials are currently ongoing (NCT04320615, NCT04345445 and NCT04330638). However, at least for tocilizumab, the clinical use in hospitalised patients with severe COVID-19 has not met the expectations in randomised clinical trials (COVACTA/ NCT04320615), and areas of implementation are now explored to identify possible predictive biomarkers of benefit for a subset of selected patients [124]. Finally, the pro-inflammatory microenvironment in COVID-19-associated lung failure induces massive infiltration of immune cells and damages the alveolar tissues. This mechanism increases vascular permeability and alveolar fluids accumulation, which is a hallmark of the deadly acute respiratory distress syndrome (ARDS) [115]. Both the mechanisms of immune-escape in COVID-19 might be potentially targetable and should be urgently delineated.

4. Potential anticancer drugs for COVID-19

4.1. Ruxolitinib

Ruxolitinib is a potent orally bioavailable Janus kinase (JAK) 1 and JAK2 inhibitor indicated for various myeloproliferative malignancies including myelofibrosis and polycythaemia vera [3,198,200]. These neoplasms, alongside with the acute myeloid leukaemia, are known by their aberrant activation of the JAK-STAT signalling [199]. This pathway plays a pivotal role in cell proliferation and survival and seems to be targetable for a spectrum of conditions beyond malignancies.

Regarding COVID-19, ruxolitinib was recently repurposed to quell the immune-hyperactivation, thus damping the cytokine storm and improving ARDS. An artificial intelligence-driven study has identified ruxolitinib as a promising drug for COVID-19 along with other molecules capable to disrupt the JAK-STAT signalling, used for myelofibrosis and rheumatoid arthritis, such as baricitinib and fedratinib [181]. The clinical trials using ruxolitinib for COVID-19 are summarised in Table 1. In particular, ruxolitinib is being investigated against placebo for COVID-19 patients with ARDS in two randomised phase III trials (NCT04362137 and NCT04377620). The
| Anticancer drug | Mechanism of action | Viral–host targets | Tested in clinical trials for COVID-19? (country) | NCT identifier | Eligible population | Primary end-point | Estimated completion date |
|-----------------|---------------------|--------------------|-------------------------------------------------|----------------|---------------------|-------------------|--------------------------|
| Ruxolitinib     | Reduction of hyperinflammation during cytokine storm | JAK-STAT pathway | Yes (USA, Germany, France, Mexico, Canada, Italy and Spain) | NCT04348071 | Hospitalised patients | Cumulative incidence of Grade 3 and 4 AE; eight-point ordinal scale | October 2021 |
|                 |                     |                    |                                                 | NCT04359290 NCT04355793 | Severe lung disease Hospitalised patients | Overall survival Description of the disease course | July 2021 Not provided |
|                 |                     |                    |                                                 | NCT04354714 NCT04362137 | Critical disease Hospitalised patients | Overall survival Proportion of patients who die, develop respiratory failure or require ICU care | Not provided November 2020 |
|                 |                     |                    |                                                 | NCT04377620 | COVID-19-associated ARDS | Overall survival | October 2020 |
|                 |                     |                    |                                                 | NCT04366232 | Hypoxic pneumonia, ARDS or end-stage organ failure | Biological criteria of response, based on biomarkers change* | September 2020 |
|                 |                     |                    |                                                 | NCT04334044 | Pneumonia with dyspnea | Recovery of pneumonia | June 2020 |
|                 |                     |                    |                                                 | NCT04374149 NCT04338958 NCT04337359 | Critical disease Severe lung disease Critical disease | Overall response rate Overall response rate Description of the disease course | April 2021 August 2021 Not provided |
|                 |                     |                    |                                                 | NCT04331665 | Disease requiring O₂-support | Rate of clinical worsening | February 2021 |
|                 |                     |                    |                                                 | NCT04361903 | Disease requiring O₂-support | Number of patients who avoid mechanical-assisted ventilation | June 2020 |
|                 |                     |                    |                                                 | NCT04348695 NCT04424056 | Hospitalised patients Eligible patients for resuscitation care in UCI | Rate of clinical worsening Ventilation-free days at day 28 | May 2020 November 2022 |
| Bevacizumab     | Vascular permeability inhibition | VEGF | Yes (France and China) | NCT04275414 | Severe lung disease or critical disease | Change of PaO₂ to FiO₂ ratio | May 2020 |
|                 |                     |                    |                                                 | NCT04344782 | Severe lung disease | Number of patients who avoid mechanical-assisted ventilation | December 2020 |
| Carmofur        | Blockade of viral replication | SARS-CoV-2 main protease | No | NCT04305106 | Disease requiring O₂-support | Time to clinical improvement | August 2020 |
| Carfilzomib     | Blockade of viral replication | SARS-CoV-2 main protease | No | — | — | — | — |
| Drug                  | Mechanism of Action                                                                 | Clinical Outcome                                                                 | Study Details                                                                 |
|----------------------|-------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Toremifene           | Inhibition of viral membranes fusion with host cell endosomes                       | Interaction with coronavirus proteins                                            |                                                                                |
| Zotatifin            | Inhibition of protein biogenesis                                                     | Blockade of eIF4A                                                                | NCT04382066 Hospitalised patients Frequency of occurrence of Grade 3 or higher AEs November 2020 |
| Plitidepsin          | Interference with the viral cycle                                                   | Blockade of eEF1A                                                               | Yes (Spain) NCT04343651 Mild/moderate disease NCT04347239 Severe lung disease or critical disease September 2020 |
| Dactinomycin         | Inhibition of viral cellular transcription inhibition                                | Inhibition of DNA topoisomerase                                                  | NCT04343144 Disease requiring O2-support NCT0433914 Disease requiring O2-support NCT04356508 Clinically stable patients with mild or moderate disease and asymptomatic patients NCT04355305 Severe lung disease or critical disease October 2020 |
| Valrubicin           | Blockade of viral replication                                                       | SARS-CoV-2 main protease                                                        | Yes (France and China) PD-1/PD-L1 pathway blockade NCT04353513 Severe lung disease or critical disease September 2020 |
| Leronlimab           | Immune homeostasis restoration                                                      | Disruption of the CCL5/RANTES-CCR5 pathway                                        | Yes (USA) NCT0434416 Disease requiring O2-support NCT0434814 Disease requiring O2-support NCT04356495 Outpatients, diagnosed <5d Critical disease February 2021 |
| Camrelizumab         | Immune homeostasis restoration                                                      | PD-1/PD-L1 pathway blockade                                                      | Yes (China) ChiCTR2000029806 Severe lung disease P13K inhibition Yes (USA) NCT04372602 Respiratory failure-free survival rate April 2021 |
| Nivolumab            | Immune homeostasis restoration                                                      | PD-1/PD-L1 pathway blockade                                                      | Yes (France and China) NCT04353513 Severe lung disease or critical disease September 2020 |
| Pembrolizumab        | Immune homeostasis restoration                                                      | PD-1/PD-L1 pathway blockade                                                      | Yes (Spain) NCT04353513 Severe lung disease or critical disease September 2020 |
| Imatinib             | Blockade of cell entry and endosomal trafficking                                   | BCR/ABL kinase inhibition                                                        | Yes (France, Spain and USA) NCT04357613 Hospitalised patients NCT04346147 Disease diagnosed <7d NCT04394416 Hospitalised patients diagnosed <7d NCT04356495 Outpatients, diagnosed <5d Critical disease December 2021 |
| Duvelisib            | Immune homeostasis restoration and viral replication inhibition                     | PI3K inhibition                                                                  | Yes (USA) NCT04372602 Respiratory failure-free survival rate April 2021 |
| Zanubrutinib         | Protection against immune, lethal and sepsis-induced pulmonary injuries            | Inhibition of the Bruton tyrosine kinase                                         | Yes (USA) NCT04382586 Disease requiring O2-support April 2021 |
| Ibrutinib            | Protection against immune-induced lung injury                                      | Inhibition of the Bruton tyrosine kinase                                         | Yes (USA) NCT04375397 Hospitalised patients with severe pneumonia April 2021 |
RUXCOVID study (n = 402, NCT04362137) is a phase III, multicentred, randomised (2:1) and placebo-controlled trial, which evaluates the safety and efficacy of ruxolitinib added to best supportive care in patients with cytokine storm. The RUXCOVID-DEVENT (NCT04377620) is a phase III, placebo-controlled trial, which is currently evaluating ruxolitinib for the treatment of COVID-19 patients with ARDS requiring mechanical ventilation. Both the phase III trials are designed for clinically critical patients, aiming to tackle the pathological immune response and control the hyper-inflammatory syndrome in more severe patients. In addition, another ongoing phase III trial (NCT04424056) combines multiple immune suppressors including anakinra (an anti-IL-1 inhibitor), tocilizumab, in association with ruxolitinib for more severe COVID-19 cases, including ARDS, associated with possible cytokine storm and other immune dysregulations.

4.2. Carmofur

Carmofur (1-hexylcarbamoyl-5-fluorouracil) is an old pyrimidine analogue and a lipophilic masked compound of fluorouracil. Its mechanism of action is independent of 5-fluorouracil-antitumour activity, based on the inhibition of the lysosomal acid ceramidase [43,148]. The upregulation of acid ceramidase is linked to survival and growth of cancer cells as well as drug resistance [23]. This enzyme is an emerging target for several malignancies [74], such as prostate cancer [108] and glioblastoma [130] as well as paediatric brain tumours [45]. In addition, carmofur exerts its antiproliferative and antimetastatic effects through the blockade of the Wnt/β-catenin signalling pathway [107]. This molecule has been previously tested in clinical trials for the treatment of colon cancer as single or in combination with other chemotherapeutics [162] and in early breast cancer [122]. Recently, carmofur has been found to block SARS-CoV-2 replication by inhibiting the viral protease through the covalent binding between the carbonyl reactive group and the catalytic Cys145. In another molecular modelling report, Gao et al. indicated that carmofur strongly bound to SARS-CoV-2 M^pro [63]. This suggests that repurposing low-molecular weight drugs such as carmofur against the main protease of SARS-CoV-2 based on in silico studies may show a therapeutic potential. Importantly, the identification of the specific mechanisms of viral blockade provided the paradigm to design analogues of carmofur, with improved efficacy for COVID-19 and less neurotoxicity. This last aspect is particularly relevant because of its association with drug-related leukoencephalopathy.

4.3. Bevacizumab

Bevacizumab is a monoclonal antibody with anti-angiogenic properties, capable to target the vascular endothelial growth factor [64]. This biological agent has
been successfully implemented in the clinic management of various cancer types, including advanced ovarian cancer, renal cell carcinoma as well as colorectal cancer in combination with chemotherapy [49,64]. The key mechanism of bevacizumab is related to the disruption of the malignant neo-angiogenesis, ultimately reducing the abnormal vascular permeability and nutrients supply to cancer cells. Based on this mechanism [15,208], the use of bevacizumab has been proposed for the control of the abnormal angiogenesis and the related vascular permeability undermining the accumulation of intra-alveolar fibrin deposition, resulting in ARDS and occurring during COVID-19 disease. A recent study found that new vessel growth induced by intussusceptive angiogenesis in the lungs of COVID-19 patients is approximately three times higher than in the lungs of patients with influenza [2]. Therefore, bevacizumab is being investigated also in this field (NCT04344782, NCT04305106 and NCT04275414). More in detail, the BEST-CP clinical trial (NCT04275414) (n = 20) is a Chinese pilot study that is currently recruiting patients with COVID-19 to be treated with intravenous bevacizumab (500 mg flat dose) with the aim to control the pulmonary oedema. Another multicentred and randomised trial in China is investigating the safety and efficacy of bevacizumab (7.5 mg/kg) in COVID-19 patients with severe pneumonia (NCT04305106). Additionally, the French CORIMMUNO-BEVA phase II trial (NCT04344782) is randomising COVID-19 patients to receive bevacizumab (7.5 mg/kg) versus best of the standard supportive care (Table 1). Based on the proposed mechanism of action, the use of bevacizumab is now included in clinical trials for more severe patients, presenting with the clinical features of ARDS.

4.4. Carfilzomib

Carfilzomib is an approved antineoplastic drug for the treatment of relapsed or refractory multiple myeloma patients who have received ≤3 previous lines of therapies [170,183,214]. It has been investigated in several clinical trials for other malignancies such as Hodgkin lymphoma (NCT02867618) and non-Hodgkin lymphoma like in diffuse large B-cell lymphoma (NCT02073097) and mantle cell lymphoma (NCT03891355). In detail, carfilzomib is a second-generation antiproteasome with higher maximal percentage of proteasome inhibition at the maximum tolerated dose than bortezomib [103]. Carfilzomib was recently repurposed for COVID-19 based on virtual docking screening, a structure-based virtual screening method for molecules capable of binding specific proteins in key binding sites or domains [206]. Among several other promising drugs, including eravacycline, elbasvir, lopinavir and valrubicin, carfilzomib was excellent in terms of binding free energy, which is an important parameter for a rational drug design targeting the SARS-CoV-2 main protease, anticipating a potent antiviral activity in silico [206].

4.5. Toremifene

Toremifene is a selective modulator of oestrogen receptors used in the endocrine therapy of breast cancer since 1997 [201]. Toremifene represents an alternative drug to tamoxifen, showing a similar efficacy in patients with advanced breast cancer [113]. Additionally, this anti-oestrogen drug was shown to destabilise the envelope glycoprotein of Ebola virus [222], leading to the inhibition of the fusion between viral and endosome membranes during intracellular trafficking [222]. The subsequent in vivo studies confirmed the anti-Ebola activity of toremifene regardless of its oestrogen-modulating activity, by inhibiting virus entry and internalisation [97].

Finally, a recent in silico study identified toremifene as a potential therapeutic approach against SARS-CoV-2, particularly when combined to emodin [225]. Emodin is a natural-derived compound with antico-virus pharmacological properties, belonging to the traditional Chinese medicine Lianhua Qingwen used for the prevention and treatment of viral influenza [84,165]. The authors suggested that toremifene interacts with several key host coronavirus proteins including ribosomal proteins like RPL19, HNRNPA1, NPM1, EIF3I, EIF3F and EIF3E [225]. However, the exact mechanism of its activity is still unclear. Based on the action on viral entry, the use of this agent can be proposed for prophylaxis of the infection and in patients with milder disease, in the earlier stages of infection.

4.6. Zotatifin

Zotatifin is a potent and selective small molecule inhibiting the eukaryotic initiation factor 4A (eIF4A) [190]. eIF4A is an RNA helicase activated by the B-cell receptor to stimulate several oncogenes linked to tumour growth, cell survival and metastasis [82,190]. The inhibition of this target by zotatifin and other synthetic molecules demonstrated promising antineoplastic preclinical efficacy [28,125,190]. For example, zotatifin is being studied in a phase I/II dose-escalation and cohort expansion clinical trial (n = 45) as monotherapy for pancreatic cancer and other malignancies (NCT04092673). Promisingly, a recent study published in Nature suggests a potential of zotatifin repurposing for COVID-19 [73]. Based on affinity-purification mass
spectrometry, the authors revealed 332 SARS-CoV-2-human protein—protein interactions after cloning and expressing the key SARS-CoV-2 proteins in human cells [73]. Importantly, 66 targetable human proteins were identified to be pharmacologically druggable by 69 compounds including 29 FDA-approved drugs [73]. Several of these compounds exhibited antiviral activities against mRNA translation and Sigma1 and Sigma2 virus receptors expressed on host cells [73]. In this study, zotatifin emerged as an effective drug in reducing viral infectivity by inhibiting protein biogenesis through eIF4A blockade along with other compounds such as ternatin-4 [73,135]. The proposed disruption of the translation of the Sigma proteins coupled to the direct inhibitory activity against them seems a promising strategy of drug targeting against SARS-CoV-2 infection and propagation, possibly indicated in the earlier stages of the infection.

4.7. Plitidepsin

Plitidepsin (also known as dehydrodidemnin B) is a natural compound discovered in a Caribbean marine organism (Aplidium albicans) [48]. Its antitumour effects encompass several cancer targets such as angiogenesis and cell survival [5,72]. Additionally, plitidepsin may also enhance radiotherapy response by a bystander effect [155]. The activation of c-Jun N-terminal kinase is a key mediator of plitidepsin sensitivity along with the eukaryotic elongation factor 1 alpha 2 that were recently suggested as potential predictive biomarkers of drug response [30,126]. So far, the drug has been investigated in several clinical trials for multiple myeloma, lymphoma, liposarcoma and prostate cancer [48]. Only one phase III randomised and controlled trial has evaluated the clinical activity of plitidepsin combined to dexamethasone in relapsed/refractory multiple myeloma (NCT01102426/ADMYRE), showing mild improvements in survival outcomes [180]. The development of this drug has been halted or terminated because of the arrival of competitive targeted agents as well as the poor enrolment in clinical trials.

On the other hand, plitidepsin has also antiviral properties, showing promising findings in the COVID-19 treatment on in vitro models (Press release 1, [136,137]). According to these models, plitidepsin blocks the eEF1A protein in human cells that is required for SARS-CoV-2 infection (Press release 2, [136,137]). Therefore, the drug is being tested in a phase I Spanish trial (NCT04382066/APLICOV) with the aim to assess the safety and early efficacy of three doses of plitidepsin (1.5, 2.0 and 2.5 mg/day) for three consecutive days in patients requiring hospitalisation for COVID-19 (n = 27). Based on the activity on a key mechanism of the viral pathogenesis, the use of this drug can be considered either in the earlier stages of infection, in a multidrug regimen and for patients with more advanced disease, together with proper immunomodulators.

4.8. Dactinomycin

Historically, the anticancer drug dactinomycin was discovered in Streptomyces parvulus bacterium by Selman Waksman and colleagues in the 1940s [203] and launched after its initial FDA-approval in 1964. This intravenously administered cytotoxic antibiotic acts by intercalation to DNA and interruption of RNA transcription [38,87]. Recently, dactinomycin was shown to induce immunogenic cell death, suggesting a direct antineoplastic activity enhanced by immunomodulatory properties [93]. In fact, this drug is used in combination with other cytotoxic drugs in the management of a broad array of solid malignancies, such as gestational trophoblastic disease, Wilms’ tumour and Ewing sarcoma [4,67,105,196].

The use of dactinomycin against coronaviruses was firstly described in 1979 by Kennedy et al. in the context of alpha-coronavirus 229E, involved in a spectrum of respiratory diseases from upper to lower airways infections [98]. Later on, Lewis et al. showed a potent inhibition of the feline enteric coronavirus strain 79-1683 in whole feline embryo cells [104]. Based on these and subsequent evidence, dactinomycin was widely used as an in vitro inhibitor of viral cellular transcription in infected cells [197]. Recently, a combination of dactinomycin and sirolimus showed a synergistic action against SARS-CoV-2-host proteins [225]. In fact, the association may inhibit DNA topoisomerase required for RNA synthesis as well as mammalian target of rapamycin (mTOR) signalling in human coronavirus infected cells [225]. Notably, the mTOR pathway is a target of sirolimus that has also shown a promising activity against MERS-CoV in addition to its known antican, immunosuppressive and antifungal properties [100]. However, these results for SARS-CoV-2 are limited by their in silico nature and warrant more clinical experiences beyond speculations. In addition, the use of this antibiotic is associated with an adverse safety profile when used at therapeutic doses as an antineoplastic agent that may be less suitable for severely ill patients with an acute infectious disease. In particular, the emetogenesis and myelosuppression can deserve a special consideration, and antiviral doses may be acceptable only if lower, as expecting a better safety profile.

4.9. Valrubicin

Valrubicin is a semisynthetic derivative of the anthracycline doxorubicin, used as intravesical topic treatment for the management of refractory non-muscle invasive bladder cancer [168]. The mechanism of action of valrubicin affects DNA synthesis and metabolism by inhibiting the incorporation of nucleosides and
topoisomerase II [13,168]. Based on computational hierarchical virtual screening, recently Wang showed that valrubicin alongside with other drugs, such as lopinavir and carfilzomib inhibits the main protease of SARS-CoV-2 [206]. Moreover, another report based on a machine-learning simulation has recently shown that valrubicin is a potential COVID-19 protease inhibitor [99]. However, no considerations on the effective doses have been modelled: the clinical use as an agent for systemic administration is not validated, being approved only as a topical solution, and any speculation for the design of clinical trials should account for the adverse safety profile of this chemotherapeutic.

4.10. Leronlimab

Leronlimab (PRO 140) is a humanised monoclonal antibody targeting the C–C chemokine receptor type 5 (CCR5) on T lymphocytes [96]. The role of CCR5 in the immunopathology of disease has been extensively studied since its discovery as a co-receptor for human immunodeficiency virus entry in 1996 [21] (NCT03902522 and NCT02859961). In addition, CCR5 is also expressed on a broad array of cancers and it is linked to various cancer hallmarks, particularly “avoiding immune destruction” [96]. It is under investigation in trials for few cancers, such as metastatic colon and breast cancers (NCT03838367), for which several other inhibitors of CCR5 are being developed (reviewed elsewhere: [96]). Previously, Chen et al. demonstrated that mRNA transcripts of CCR5 and other chemokine receptors were found upregulated in animals infected by SARS-CoV [30]. Additionally, enhanced production of these mediators was associated with recruitment of inflammatory cells and T lymphocytes influx into the lung parenchyma [30].

PRO 140 has shown a promising antiviral potency with a high barrier to resistance and encouraging short-term safety and tolerability [189]. A recently published Preprint suggested that leronlimab disrupts the CCL5/RANTES-CCR5 axis and restores immune homeostasis in COVID-19 patients [133]. The authors observed a marked CCR5 receptor occupancy on macrophages and T lymphocytes, rapid drop of circulating IL-6, CD4/CD8 ratio restoration and a significant decrease of patients’ viremia [133]. These encouraging findings boosted the rapid entrance of leronlimab into two clinical trials for mild to moderate and severe COVID-19 infection (NCT04343651 and NCT04347239). The largest trial using this drug is a randomised, double-blind and placebo-controlled, two-arm phase Ib/III trial investigating weekly leronlimab at a dose of 700 mg given subcutaneously (NCT04347239). A multicentred enrolment will include 390 patients with severe or critical disease with a mortality rate after four weeks of treatment as a primary end-point. Likewise, the other study is a phase II (n = 75) with a similar design that will enrol patients with mild to moderate symptoms (NCT04343651). Patients will be randomised to receive leronlimab (700 mg) or placebo weekly in a 2:1 ratio with changes in total symptom score based on fever, myalgia, dyspnea and cough at day 14 as a primary end-point. Notably, the other outcome measures in this clinical trial include serum changes of cytokines and chemokines from baseline, CCR5 occupancy levels on macrophages and T\(^+\) cells and CD3+, CD4+ and CD8+ T cell count from baseline. Based on the specific action in-between the viral pathogenesis and the immune-dysregulation, the use of this agent has been proposed for patients with mild clinical COVID-19 to prevent severe outcomes and reduce the related mortality.

4.11. Antineoplastic immune-checkpoint inhibitors

Based on the hypothesis suggesting the upregulation of immune-checkpoints such as PD-1/PD-L1, cytotoxic T lymphocyte antigen-4 (CTLA-4), lymphocyte activation-gene-3 (LAG-3) and T cell membrane protein-3 (TIM-3) pathways in excessive inflammatory response during sepsis [132], these types of drugs were repurposed beyond their use for the treatment of cancers [132,147]. Importantly, a recent meta-analysis including four studies showed PD-1 blockade improves patient outcome in sepsis [219].

Camrelizumab is a humanised IgG4-kappa anti-programmed cell death 1 (PD-1) monoclonal antibody used in cancer immunotherapy [114]. The blockade of PD-1 binding to its ligand PD-L1 enables reactivation of cell-mediated immune response against cancer cells [114]. Camrelizumab was tested in phases II/III clinical trials for advanced or metastatic oesophageal squamous cell carcinoma [91,92], osteosarcoma [212], relapsed or refractory classical Hodgkin lymphoma [177,178] and advanced hepatocellular carcinoma [145]. It received its first approval in China for treating RRHCL patients who received at least two lines of chemotherapy [114]. Additionally, it is currently being studied in two ongoing phase III trials for local advanced nasopharyngeal carcinoma (NCT03427827) and gastric and gastroesophageal junction adenocarcinoma (NCT04208347). The use of anti-PD-1 inhibitor camrelizumab in COVID-19 patients with pneumonia is being evaluated in a Chinese clinical trial (n = 120; ChiCTR2000029806) in comparison with the standard supportive care and the immunomodulatory agent thymosin.

Nivolumab and pembrolizumab are other immune-checkpoint inhibitors (ICIs) that were successfully introduced into the management of various solid cancers, particularly for melanoma [110,204]. These ICIs are both humanised and fully human anti-PD-1 IgG4 monoclonal antibodies. Their marked clinical activity depends on PD-L1 expression in some tumours, as well as on emerging predictive biomarkers, such as tumour-
Nivolumab is currently used in a multicentred phase II trial comparing its efficacy against tocilizumab, GNS561 (a chloroquine analogue), and standard supportive care in advanced or metastatic cancer patients with COVID-19 (NCT04333914). A total of 273 participants will be randomised to receive one of three treatments based on two cohorts. Patients that are asymptomatic or with mild disease will be prospectively assigned to the group comparing nivolumab versus GNS561 versus standard of care in a 1:1:1 ratio. Similarly, in patients with moderate to severe symptoms, nivolumab will be compared to GNS561 and tocilizumab. Survival after four weeks of randomised treatment is the primary end-point in this trial. Moreover, another ongoing French phase II trial (n = 92) is investigating the safety and efficacy of nivolumab in COVID-19 patients requiring hospitalisation (NCT04343144). Patients will be randomly allocated to receive nivolumab or standard of care (1:1 ratio). One pilot trial is also testing nivolumab in the earlier setting of COVID-19, in patients presenting with no or mild symptoms and not hospitalised — to examine the role of this ICI as an immune-enhancer, to accelerate the clearance of SARS-CoV-2 (NCT04356508).

Pembrolizumab was also repurposed for COVID-19. The COPERNICO is a multicentred two-arm phase II trial (NCT04335305) that is currently enrolling patients with COVID-19 associated with pneumonia in Spain and who are non-responsive to frontline therapy. Twenty-four participants will be prospectively randomised to receive intravenous tocilizumab plus pembrolizumab or standard treatments (at physician’s choice). The use of ICIs for COVID-19 is essentially intended as an immunomodulator, based on the proposed role of PD-L1 axis in the pathogenesis of ARDS and the expedited clearance of SARS-CoV-2 with anti-PD-L1 therapies [163].

Accordingly, the studies ongoing are testing these ICIs both for more severe cases, intending to attenuate the exuberant cytokine production [166], and for mild presentations, to prevent the onset of the hyper-immune pathological response and then dampen the viral replication [163]. Moreover, a recent report showed that PD-1 checkpoint inhibition in lung cancer patients who were diagnosed with COVID-19 does not appear to affect the prognostic outcomes [111]. Therefore, this provides a promising rationale for immunotherapy, which seems to have no unfavorable effects in this setting.

4.12. Kinase inhibitors

The blockade of kinase cascade is one of the successful targeted strategies in treating cancer in the modern era of oncology. Several kinase inhibitors including palbociclib, crizotinib, dabrafenib and imatinib, were introduced in practice for various cancers [69]. The rationale for using kinase inhibitors in COVID-19 is principally based on their ability to inhibit host intracellular-viral events particularly during trafficking induced during the viral life cycle [140]. Viruses commonly use a number of host kinases during their invasion and thus, they are considered potential targets for kinase inhibitors repurposing as broad-spectrum antivirals [66,164]. Several previous reports demonstrated potent antiviral properties for kinase inhibitors in various virus-induced diseases, including SARS-CoV infections [8,17,35,46,100,128,129].

Imatinib is a marketed tyrosine kinase inhibitor for chronic myeloid leukaemia and gastrointestinal stromal tumours in the first-line setting [34,85]. The BCR-ABL1 oncoprotein with kinase activity was found to mediate virus entry in several reports encompassing hepatitis C and Ebola viruses [65,120]. In coronaviruses, recent studies indicated that imatinib blocks cell–cell and cell–virus membrane fusions [36,175]. Additionally, in vivo and ex-vivo mouse models, the use of imatinib protected the lungs from ischemia/reperfusion injury [112,187], attenuated inflammation and vascular leak [154] and prevented lung injury and death [182].

Clinically, the IMAGE-19 trial is a single-arm phase II study in France that will enrol 90 elderly COVID-19 patients (NCT04357613). Early imatinib therapy at a dose of 100 mg is also being examined in combination with hydroxychloroquine in the Spanish Covid-19HUF phase II trial (n = 165) (NCT04346147). Participants will be randomised to receive either oral lopinavir/ritonavir (protease inhibitors), imatinib or baricitinib (JAK inhibitor), all combined to hydroxychloroquine. The trial completion date is estimated in September 2020.

The COVERAGE study is a large French multiarm phase III trial (NCT04356495) that will investigate the efficacy of imatinib and several other experimental treatments. A total of 1057 symptomatic COVID-19 patients will be randomly allocated to receive imatinib, or telmisartan, or favipiravir, or hydroxychloroquine. The efficacy of imatinib at a dose of 800 mg daily for two weeks will be evaluated to prevent the progression to severe disease in patients >70 years with COVID-19. The efficacy of imatinib at a dose of 100 mg is also being examined in combination with hydroxychloroquine in the Spanish Covid-19HUF phase II trial (n = 165) (NCT04346147). Participants will be randomised to receive either oral lopinavir/ritonavir (protease inhibitors), imatinib or baricitinib (JAK inhibitor), all combined to hydroxychloroquine. The trial completion date is estimated in September 2020.

The COVERAGE study is a large French multiarm phase III trial (NCT04356495) that will investigate the efficacy of imatinib and several other experimental treatments. A total of 1057 symptomatic COVID-19 patients will be randomly allocated to receive imatinib, or telmisartan, or favipiravir, or hydroxychloroquine. The efficacy of imatinib at a dose of 800 mg daily for two weeks will be evaluated to prevent the progression to severe disease in patients >70 years with COVID-19. The efficacy of imatinib at a dose of 100 mg is also being examined in combination with hydroxychloroquine in the Spanish Covid-19HUF phase II trial (n = 165) (NCT04346147). Participants will be randomised to receive either oral lopinavir/ritonavir (protease inhibitors), imatinib or baricitinib (JAK inhibitor), all combined to hydroxychloroquine. The trial completion date is estimated in September 2020.
contagiousness among people and prevent the progression to severe COVID-19.

Duvelisib is an orally bioavailable phosphatidylinositotol 3-kinase (PI3K) selective inhibitor that is being studied for haematologic malignancies [94]. The PI3K–AKT–mTOR signalling is frequently dysregulated in cancer as well as during hyperinflammation and its therapeutic targeting is highly represented in ongoing clinical trials. Duvelisib was investigated in the DUO phase III trial and compared to ofatumumab for refractory and relapsed chronic lymphocytic leukaemia and small lymphocytic lymphoma [59]. It was approved by the FDA in 2018 for treating adult patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia after at least two prior therapies [88]. There is currently one pilot phase II trial examining the efficacy of duvelisib twice daily at a dose of 25 mg for 10 d in COVID-19 patients as monotherapy (NCT04372602). This single-arm study will test the hypothesis that PI3K blockade could hamper the immune system hyperactivation and therefore reduce lung inflammation and interfere with the viral cycle. It is estimated to enrol 25 participants, with overall survival as a primary end-point. Notably, the PI3K inhibitors including the drug duvelisib can cause lung inflammation and increase the risk for infections, as consistently demonstrated for multiple compounds of this pharmacological class, and a special caution is warranted during the clinical trials using this class of molecules.

The aberrant activation of the Bruton tyrosine kinase has a key role in the tumourigenesis of B-cell lymphoma [77]. Its aberration seems to protect lungs from acute immune-induced or lethal influenza-induced injuries [60,102] as well as sepsis-induced injury [224]. Zanubrutinib is an orally administered irreversible inhibitor of the Bruton tyrosine kinase [186,218,220]. This drug showed a durable and high overall response rate in patients with relapsed/refractory Mantle cell lymphoma [179]. Recently, zanubrutinib received accelerated FDA approval for treating adult patients with this rare and aggressive cancer who have received at least one line of therapy [186]. For COVID-19, a phase II trial in the United States is ongoing, aiming to dampen the disease-related immune dysregulation and hyper-inflammation (NCT04382586). This study is expected to randomise 52 participants to receive zanubrutinib combined to supportive care versus placebo to test the hypothesis of increasing respiratory failure-free survival rates in patients with pulmonary distress. Ibrutinib is another inhibitor of Bruton kinase inhibitor, approved to treat indolent B-cell malignancies and chronic graft-versus-host disease, now being repurposed for COVID-19 [193]. An earlier experience with this drug in COVID-19 patients with cancer showed marked improvements and resolution or near resolution of COVID-19 symptoms during the follow-up [193]. In the same way, the iNSPIRE (NCT04375397) is a phase II that will enrol 46 COVID-19 patients to randomly receive ibrutinib versus placebo along with standard supportive care. The trialists expect that ibrutinib will reduce respiratory failure and their findings are expected to be released in September 2020.

Opaganib (ABC294640) is a first-in-class selective inhibitor of sphingosine kinase-2 (sk2). This key enzyme in lipid signalling promotes tumour growth, cell proliferation and cytokine production during inflammation [139,143,176–178]. It was previously noticed that sk2 is the host factor that impacts the viral replication process of the chikungunya virus [149] and maintains viral latency and survival in Kaposi’s sarcoma-associated herpes virus [39]. This drug has an orphan drug designation for cholangiocarcinoma [89] and is being tested in clinical trials for patients with metastatic castration-resistant prostate cancer (NCT04207255) and advanced cholangiocarcinoma (NCT03377179). It is also under development for COVID-19-associated pneumonia in a phase II study (NCT04414618). This is a randomised, double-blind, placebo-controlled trial in 40 adult patients with positive pneumonia, using daily opaganib for two weeks.

Saracatinib (AZD0530) is a tyrosine kinase inhibitor of the c-SRC family of proto-oncogenes. This pathway mediates signal transduction for several cell functions such as proliferation, cell-to-cell transmission, epithelial-to-mesenchymal transition, vascular permeability, invasion and metastasis [33,131]. Moreover, it interferes with additional cell signalling such as PI3K/mTOR and MAPK [151]. Saracatinib selectively abrogates this enzyme and was investigated in several clinical trials for recurrent osteosarcoma [11], platinum-resistant ovarian cancer [116], unresectable thymic malignancy [76] and cancer-induced bone pain [41]. SRC kinases have also a role in endocytic trafficking [150] and there is a growing body of evidence indicating the inhibitory properties of viral replication of dengue viruses and MERS-CoV by the anticancer agent saracatinib [42,171,228]. This makes this drug a possible candidate for further investigations on other members of the Coronaviridae family. In a recently published Preprint, molecular modelling showed that saracatinib binds to the nucleocapsid protein sites of SARS-CoV-2 along with other previously discussed drugs such as imatinib and camostat [188]. To the best of our knowledge, saracatinib has not entered into any COVID-19 clinical trial. The clinical use of molecular blockers of PI3K–AKT–mTOR, Bruton tyrosine kinase, sk2 and c-SRC is anticipated to exert immune-modulating rather than antiviral effect. To date, the drug development of this group of tyrosine kinase inhibitors is included in the protocols for hospitalised patients with severe COVID-19, to rescue the immune-dysregulation and improve the outcome.
4.13. Selinexor

Selinexor is a first-in-class orally bioavailable inhibitor of Exportin-1 (XPO1) [185]. XPO1 is an export receptor for various proteins and RNA molecules with oncogenic properties and is frequently altered in cancer [7]. Moreover, it is implicated in several cancer pathways including cell growth and survival, differentiation and drug resistance [127]. XPO1 suppression by selinexor in human clinical trials demonstrated promising results for patients with heavily treated relapsed or refractory multiple myeloma [29,152,202]. The drug received first an accelerated approval by the FDA in the United States of America (USA) in 2019 in combination with dexamethasone [152]. The antiviral activity of selinexor is based on its potential to interfere with host targets including XPO1 that interacts with SARS-CoV-2 proteins [73,194]. In fact, blockade of this nucleocytoplasmic transporter can sequester viral materials in the host cell nucleus and therefore reduce its replication mechanisms and viral load [194]. Moreover, selinexor has also selective and potent anti-inflammatory effects on sepsis pathophysiology [211]. Based on these concepts, two phase II randomised and controlled trials of low dose selinexor were initiated for COVID-19 patients with moderate to severe disease (NCT04355676 and NCT04349098). The largest trial that is currently recruiting patients is single-blind and placebo-controlled and is expected to enrol 230 hospitalised participants with severe COVID-19 (NCT04349098).

5. Perspectives

The COVID-19 pandemic continues to spread globally with 24,484,968 cases and 832,533 deaths registered worldwide, including 6,016,069 cases only in the USA (as of 27th August 2020). New effective therapeutics are urgently needed, as the results from the first clinical trials or experiences with drugs for COVID-19 are mostly disappointing. There is a massive demand for drug repurposing in this rapidly evolving setting, relying on the benefit of a shorter drug development and the capability to turn preclinical intuitions in clinical experiences. In fact, it is a potential successful drug discovery process, more efficient and resource sparing than the classic drug development from early phases for new molecules, taking generally a longer time (typically 10–15 years). While drug repurposing is not an excuse to design low-quality clinical trials or emphasise biased results from preliminary findings and non-controlled cohorts, the possibility to use molecules with an established safety profile certainly represents an advantage. The US ClinicalTrials.gov database shows that ≥3100 clinical studies for COVID-19, including more than 1700 interventional trials (accessed as of 27-08-2020), are ongoing, portraying the commitment of the global medical community to accelerate the COVID-19 research agenda – in a successful interplay between laboratory researchers and clinical trialists, ultimately to serve clinicians and improve patients’ care. However, in the urgent need to provide a response to a burning unmet need, many isolated smaller clinical trials or off-label use of medicines outside the investigations have been observed, perhaps fragmenting the research agenda in uncoordinated silos — thus diluting the research efficiency. The large proportions of ongoing clinical trials are single-centred observational studies with high risk of bias and therefore providing low level of evidence when their findings are reported. The capacity to inform the decision-makers is inevitably weak when the clinical studies generate doubts over certainties. This was recently outlined in a critical appraisal of registered COVID-19 trials on ClinicalTrials.gov database [141]. In fact, only 13.6% of these clinical trials are prospective cohorts that may provide level 2 evidence [141]. Therefore, the lack of effective international cooperation is suggested, along with the negligence of other key aspects to tackle the pandemic, including the disease prevention in high-risk populations. Another emerged critical issue is the tremendous heterogeneity in the rates of COVID-19 new cases across different geographic areas with a significant decline in some countries that may halt and decrease expected enrolment in ongoing clinical trials [192]. The important number of launched monocentric studies and the observed decline of incident COVID-19 cases in some countries should promote considering adaptive study designs to fulfil enrolment [192]. For this perspective, trialists are encouraged to follow master protocols when testing their hypotheses, as suggested by the World Health Organization, in the design of the international adaptive trial SOLIDARITY (e.g. NCT04330690). A significant experience with master protocols in oncology and haematology was achieved, which may accelerate drug development and reduce ineffectiveness in urgent clinical trials [184].

Among the dozens of coronavirus drugs that are being repurposed or in development, a number of anticancer compounds are also being studied as potential future drugs for COVID-19. At this time, the best option for patients is the enrolment in clinical trials. In the current scenario where no drug has provided a “parachute” effect on the prognosis of patients with COVID-19, especially with more severe disease, the use of off-label medicines based on over-emphasised interpretations of the preliminary data from small cohorts or anecdotes is strongly discouraged. With nearly one thousand clinical trials ongoing, there is virtually room to allocate much more patients in truly promising clinical trials, tailoring specific populations across the continuum of care — from the prevention to the treatments and palliative care. The notion is clear: treatment options in settings of high medical unmet need can be improved only in controlled clinical trials, both offering the most innovative
therapeutic approaches and prompting the disengagement from established clinical interventions with narrow added value, a common contingency observed when no treatment is available for a particular disease. Having an impact on health requires quality behind.

In response to the “high clinical unmet need” and to support clinicians, who are facing the daily challenges with the aim to manage severe health conditions associated with dismal prognosis, the implementation of clinical trials may serve to boost the access to treatments, making sure of such precious information. In fact, the off-label use of some medicines, most strikingly hydroxychloroquine almost everywhere, outside a clinical trial or a registry-based accountability is the primum error and the enhancer of confusions — generated by the disconnect between the anecdotal clinical perception of benefits and the objective data collected. In this regard, the regulatory agencies for medicines in many regions and countries have reformulated simplified procedures and supported more flexibility in the design, evaluation and adoption of clinical trials, to meet the patients’ needs. For example, the European Medicines Agency (EMA) has delineated regulatory flexibilities to help pharmaceutical companies cope with the consequences of the pandemic, emphasising the need to keep high-level of quality, safety and efficacy for medicinal products developed for COVID-19. The message is clear: patients’ safety and quality of science in clinical trial conduction is non-negotiable [52] (accessed 30-05-2020). EMA has established rapid procedures through accelerated scientific advice, rolling review and expedited treatment of the applications for marketing authorisations [53] (accessed 30-05-2020).

The harmonisation of regulatory processes and enhanced drug development must necessarily proceed in parallel, committing to accelerate the drug repurposing, ensuring safety thus prompting early interruptions of trials when new safety signals emerge, or major results of activity are collected. However, while endorsing the acceleration in the revisions, decisions, approval and authorisation, the regulators should commit to ensure the design of quality clinical trials, pushing for the definition of the benefits based on patients’ relevant end-points and dissecting the reasonability and opportunity to favour surrogate endpoints in selected instances — when appropriate for the setting and highly predictive or correlated with the mortality outcomes — the truly important ones.

The high-throughput screening of approved molecules capable to dock to the key protein domains of SARS-CoV-2 pathogenesis or related to the immune-dysregulation will identify thousands of possible compounds, from in silico models. An important success for this approach was recently achieved based on a library profiling of approximately 12,000 clinical-stage or FDA-approved compounds [153]. The authors of this paper published in Nature identified various molecules such as the kinase inhibitor apilimod that antagonise SARS-CoV-2 replication in vitro and in primary human lung explant model [153]. While it is essential to boost the drug-discovery based on approved medicines, to accelerate the drug development overall, the construct of preclinical models should be in vitro and ex vivo strictly.

| Box 1. Recommended reading of particular interest | DOI |
|-----------------------------------------------|-----|
| Larson C et al. COVID-19 and Cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making. | https://doi.org/10.1016/j.bbcan.2020.188412 |
| Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2020; 188412. | |
| Zeggini E et al. Biomedical Research Goes Viral: Dangers and Opportunities. Cell. 2020; S0092-8674(20)30576-6. | |
| Sanders et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 10.1001/jama.2020.6019 | |
| Mercurelli B et al. Drug Repurposing for Viral Infectious Diseases: How Far Are We? Trends Microbiol. 2018; 26(10):865–876. | |
| Farha MA, Brown ED. Drug repurposing for antimicrobial discovery. Nat Microbiol. 2019; 4(4):565–577. | |
| Boldescu V et al. Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond. Nat Rev Drug Discov. 2017; 16(8):565–586. | |
| Takizawa N, Yamasaki M. Current landscape and future prospects of antiviral drugs derived from microbial products. J Antibiot (Tokyo). 2017; 71(1):45–52. | |
| Kaufmann SHE et al. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. 2018; 17(1):35–56. | |
| Pfefferle S et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoSPathog. 2011; 7(10):e1002331. | |
| Zumla A et al. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016; 15(5):327–347. | |
| de Wit E et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14(8):523–534. | |
| Mercorelli B et al. Drug Repurposing | |
| Zeggini E et al. Biomedical Research Goes Viral: Dangers and Opportunities. Cell. 2020; S0092-8674(20)30576-6. | |
| Sanders et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 10.1001/jama.2020.6019 | |
| Mercurelli B et al. Drug Repurposing for Viral Infectious Diseases: How Far Are We? Trends Microbiol. 2018; 26(10):865–876. | |
| Farha MA, Brown ED. Drug repurposing for antimicrobial discovery. Nat Microbiol. 2019; 4(4):565–577. | |
| Boldescu V et al. Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond. Nat Rev Drug Discov. 2017; 16(8):565–586. | |
| Takizawa N, Yamasaki M. Current landscape and future prospects of antiviral drugs derived from microbial products. J Antibiot (Tokyo). 2017; 71(1):45–52. | |
| Kaufmann SHE et al. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. 2018; 17(1):35–56. | |
| Pfefferle S et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoSPathog. 2011; 7(10):e1002331. | |
| Zumla A et al. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016; 15(5):327–347. | |
| de Wit E et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14(8):523–534. | |
implemented in collaborating research facilities, committed for the research on COVID-19. This is an effort of everyone. In the fight against COVID-19, the entire chain of medical researches has rapidly become multidisciplinary, truly intersected with specialists of several branches, transversally positioned. Offering technology and knowledge to develop the best science at the service of a public health global emergency recalls the humanitarian mandate of medical science to improve population health and wellbeing for all. The hope is that drug repurposing to boost the discovery of new treatments for human diseases will find the right place and that this innovative and transversal operational model of scientific research will get common, to result in timely impact on populations at the most effective and efficient utilisation of resources and knowledge. Time for wasteful duplications based on competitive conflicts should be over; the COVID-19 will enlighten the solidarity in science, sublimating narcissism for the ultimate goals of serving people, especially when facing the hardest moments of their lives, for deadly diseases.

### 6. Conclusion

Controlling the SARS-CoV-2 pandemic warrants multidisciplinary collaboration to find relevant treatment options. From the evidence reviewed here, a number of anticancer drugs seem to retain a promising activity to treat patients with COVID-19. The high level of evidence should still be the primary objective of the clinical research, despite the critical circumstances during a pandemic. Hence, testing a battery of known drugs in clinical cohorts will certainly provide an additional value to these molecules (for more information, see Boxes I and 2). Although the ideas of using repurposed anticancer drugs might be criticised because of the toxicity profile of some of them, we believe that this review article may provide inputs and guide the future directions for clinical research—envisioning an approach beyond the definition of separate medical subjects by vapourising the common barriers between medical disciplines. This might help address innovative operational models and regulatory flexibilities in this unique momentum of the international research, united to control a global pandemic, committed to serve the people in all over the world.

### Funding

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

### Conflicts of interest statement

Khalid El Bairi, Dario Trapani, Angelica Petrillo, Cécile Le Page, Hanaa Zbakh, Bruno Daniele, Prof. Rhizlane Belbaraka and Prof. Said Afqir have no COI to declare. Prof. Giuseppe Curigliano has received honoraria from Pfizer, Novartis, Lilly, Roche; fees for expert testimony and medical education from Pfizer and has participated in advisory boards for Pfizer, Roche, Lilly, Novartis, Seattle Genetics, Celltrion.

### Acknowledgements

For transparency and scientific publishing ethics, we supported our manuscript by the Turnitin® report of plagiarism (Supplemental material 1). To encourage international collaboration and continuous discussion of this subject, we have created a project on ResearchGate social network and we encourage the readers to ask questions and comment on the topic following this link: [https://www.researchgate.net/project/COVID-19-Cancer-and-Biomarkers](https://www.researchgate.net/project/COVID-19-Cancer-and-Biomarkers).

### Appendix A. Supplementary data

Supplementary data to this article can be found online at [https://doi.org/10.1016/j.ejca.2020.09.014](https://doi.org/10.1016/j.ejca.2020.09.014).

### References

[1] Abubakar I, Aliyu SH, Arumugam C, Hunter PR, Usman NK. Prevention and treatment of cryptosporidiosis in...
Cytotoxic antibiotics. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.

Dang W, Xu L, Ma B, et al. Nitazoxanide inhibits human norovirus replication and synergizes with ribavirin by activation of cellular antiviral response. Antimicrob Agents Chemother 2018; 62(1). https://doi.org/10.1128/AAC.00707-18. e00707-18. Published 2018 Oct 24.

Danson S, Mulvey MR, Turner L, et al. An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain. J Bone Oncol 2019;19:100261. https://doi.org/10.1016/j.jbo.2019.100261. Published 2019 Sep 18.

Di Cosimo S, Malfetton A, Pe ́rez-Garcı´a JM, et al. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of COVID-19. J Eur Can 2020;155:62–5. https://doi.org/10.1016/j.ejca.2020.05.026.

Doan NB, Nguyen HS, Montoure A, et al. Acid ceramidase is a novel drug target for pediatric brain tumors. Oncotarget 2017; 61. https://doi.org/10.18632/oncotarget.15800.

Dyall J, Gross R, Kindrachuk J, et al. Middle East respiratory syndrome coronavirus 2. J Phys Chem Lett 2020;11:7267–81. https://doi.org/10.1021/acs.jpcl.0c03970.

El Bairi K, Amrani M, Afqir S. The arrival of new, efficient, broad spectrum antivirals. Virus Res 2019;264:123ra24.

El Bairi K, Atanasov AG, Amrani M, Afqir S. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Drug Discov 2018;17(5):353–77. https://doi.org/10.1038/nrd.2018.21.

El Bairi K, Jabi R, Trapani D, et al. Can the microbiota predict survival? The answer is in the gut [published online ahead of print, 2020 aug 20].

El Bairi K, Jabi R, Trapani D, et al. Can the microbiota predict survival? The answer is in the gut [published online ahead of print, 2020 Mar 26].

El Bairi K, Jabi R, Trapani D, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/PLL. Blood 2018;132(23):2446–55. https://doi.org/10.1182/blood.2018-05-80461.

El Bairi K, Atanasov AG, Amrani M, Afqir S. Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers. Canc Med 2018;7(6):2221-2246. https://doi.org/10.1002/cam4.1467.

El Bai K, Amrani M, Kandhro AH, Afqir S. Prediction of therapy response in ovarian cancer: where are we now? Crit Rev Clin Lab Sci 2017;54(4):233–66. https://doi.org/10.1080/10408363.2017.1313190.

El Bai K, Atanasov AG, Amrani M, Afqir S. The arrival of predictive biomarkers for monitoring therapy response to natural compounds in cancer drug discovery. Biomed Pharmacother 2019;109:2492-2498. https://doi.org/10.1016/j.biopha.2018.11.097.

El Bai K, Jabi R, Trapani D, et al. Can the microbiota predict systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut [published online ahead of print, 2020 May 24]. Expet Rev Clin Pharmacol 2020;14(5):561-584. https://doi.org/10.1080/17440728.2020.1755863.

EMA. EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines. 2020. Available at: https://www.ema.europa.eu/en/documents/other/ema-initiatives-acceleration-development-support-evaluation-procedures-covid-19-treatments-vaccines_en.pdf. [Accessed 30 May 2020].

EMA. EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines. 2020. Available at: https://www.ema.europa.eu/en/documents/other/ema-initiatives-acceleration-development-support-evaluation-procedures-covid-19-treatments-vaccines_en.pdf. [Accessed 30 May 2020].

Egeris J, Sun Y, Pratt J, Bonstaff K, Voelkel-Johnson C, et al. Observational study of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med 2020;382(25):2411–8. https://doi.org/10.1056/NEJMoa2012410.

Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1–23. https://doi.org/10.1007/978-1-4939-2438-7_1.

Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov 2018;17(5):533–77. https://doi.org/10.1038/nrd.2018.21.

Florence JM, Krupa A, Booshehri LM, Davis SA, Matthay MA, Kurdowska AK. Inhibiting Bruton’s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 2018;315(1):L52-L58. https://doi.org/10.1152/ajplung.00047.2018.

Flinn IW, Hillmnen P, Montillo M, et al. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med 2020;18(1):164. https://doi.org/10.1186/s12967-020-02339-3.

Foord K, Jabi R, Trapani D, et al. Current management and future approaches through collaboration. J Clin Oncol 2015;33(27):3036.e1-30390. https://doi.org/10.1002/jcrc.2020.03.005 [published online ahead of print, 2020].

Frolov B, Zhang H, Liu X, et al. Repurposing low-molecular-weight compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers. Canc Med 2018;7(6):2221-2246. https://doi.org/10.1002/cam4.1467.

Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: new, efficient, broad spectrum antivirals. Virus Res 2019;264:123ra24.

Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Canc Treat Rev 2020;86:102017. https://doi.org/10.1016/j.ctrv.2020.102017 [published online ahead of print, 2020 Mar 26].

Garcia M, Cooper A, Shi W, et al. Productive replication of Ebola virus is regulated by the c-Abl tyrosine kinase. Sci Transl Med 2012;4(123). https://doi.org/10.1126/scitranslmed.3003500.123ra24.

Garcia-Serradilla M, Risco C, Pacheco B. Drug repurposing for new, efficient, broad spectrum antivirals. Virus Res 2019;264:123ra24.
Govindarajah N, Clifford R, Bowden D, Sutton PA, Parsons JL, Guo Y, Liu Y, Hu N, et al. Discovery of zanubrutinib (BGB-4122) as a selective and potent covalent inhibitor of Bruton’s tyrosine kinase. J Med Chem 2019;62(17):7923-3111, a novel, potent, and selective covalent inhibitor of bruton’s tyrosine kinase. J Med Chem 2019;62(17):7923–40. https://doi.org/10.1021/acs.jmedchem.9b00687.

Guy RK, DiPaola RS, Romanelli F, Dutch RE. Rapid repurposing of drugs for COVID-19. Science; 2020. https://doi.org/10.1126/science.abb9332. eabb9332.

Haffizulla J, Hartman A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 2014;14(7):690–18. https://doi.org/10.1016/S1473-3099(14)70717-0.

Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol 2020;38(4):379–81. https://doi.org/10.1038/s41581-020-00003-1.

Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Canc 2019;19(3):133–150. https://doi.org/10.1038/s41568-019-0116-x.

Heerma J, Hartman A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 2014;14(7):690–18. https://doi.org/10.1016/S1473-3099(14)70717-0.

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020. https://doi.org/10.1016/j.cell.2020.02.052 [published online ahead of print, 2020 Mar 4].

Hollstein U. Actinomycin. Chemistry and mechanism of action. Chem Rev 1974;65:25–9.

https://www.fda.gov/drugs/resources-information-approved-drugs/duvelisib-copiktra-verastem-inc-adult-patients-relapsed-or-refractory-chronic-lymphocytic-leukemia.

https://www.redhatblog.com/RedHill-Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=1365&PID=0&IID=5106. Accessed 06-06-2020.

Hu TY, Frieman M, Wolfram J. Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol 2020;15(4):247–9. https://doi.org/10.1038/s41565-020-0674-9.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 [published correction appears in Lancet. 2020 Jan 30;].

Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCOR-T): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2020. https://doi.org/10.1016/S1470-2045(20)30110-8 [published online ahead of print, 2020 May 13] S1470-2045(20)30110-30118.

Humeau J, Sauvat A, Cerrato G, et al. Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. EMBO Mol Med 2020;12(5):e11622. https://doi.org/10.15252/emmm.201911622.

Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol 2018;15(5):273–91. https://doi.org/10.1038/nrclinonc.2018.28.

Jasenosky LD, Cadena C, Mire CE, et al. The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits Ebola virus. Science; 2019;19:1279–90. https://doi.org/10.1126/sciadv.2017.007.003.

Jiao X, Nawab O, Patel T, et al. Recent advances targeting CCR5 for cancer and its role in immunology. Canc Res 2019;79(19):4801–7. https://doi.org/10.1158/0008-5472.CAN-19-1167.

Johansen LM, Brannan JM, Delos SE, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 2013;5(190). https://doi.org/10.1126/scitranslmed.3005471. 190ra79.

Kennedy DA, Johnson-Lussenburg CM. Inhibition of coronavirus 229E replication by actinomycin D. J Virol 1979;29(1):401-404.

Khandelwal R, Nayarisseri A, Madhavi M, et al. Shape-based machine learning models for the potential novel COVID-19 protease inhibitors assisted by molecular dynamics simulation. Curr Top Med Chem 2020. https://doi.org/10.2174/1568026620660200704135327 [published online ahead of print, 2020 jul 4].

Kindrachuk J, Ork B, Hart BJ, et al. Antiviral potential of remdesivir for patients with severe covid-19 [published online, 2020 Apr 17] S1931-3128(20)30236-5.

Koivuniemi A, Kääriäinen H, Pakarinen A, et al. Antiviral potential of camostat mesylate for COVID-19 [published ahead of print, 2020 Jul 4]. S1470-2045(20)30059-8.

Koivuniemi A, Kääriäinen H, Pakarinen A, et al. Antiviral potential of camostat mesylate for COVID-19 [published ahead of print, 2020 Jul 4]. S1470-2045(20)30059-8.

Koivuniemi A, Kääriäinen H, Pakarinen A, et al. Antiviral potential of camostat mesylate for COVID-19 [published ahead of print, 2020 Jul 4]. S1470-2045(20)30059-8.
complex-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 2014;307(6):L435–48. https://doi.org/10.1152/japplphysiol.00234.2013.

[103] Landgren O, Sonneveld P, Jakubowiak A, et al. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia 2019;33(9):2127–2143. https://doi.org/10.1038/s41375-019-0517-6.

[104] Lewis EL, Harbour DA, Beringer JE, Grinsted J. Differential in vitro inhibition of feline enteric coronavirus and feline infectious peritonitis virus by actinomycin D. J Gen Virol 1992;73(Prt 12):3285–3288. https://doi.org/10.1099/0022-1317-73-12-3285.

[105] Li J, Li S, Yu H, Wang J, Xu C, Lu X. The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: a network meta-analysis. Gynecol Oncol 2018;148(2):247–253. https://doi.org/10.1016/j.gyno.2017.11.031.

[106] Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19 [published online ahead of print, 2020 Mar 5]. J Pharm Anal 2020. https://doi.org/10.1016/j.jpha.2020.03.001.

[107] Liu P, Ma S, Liu H, Han H, Wang S. HCFU inhibits cervical cancer cells growth and metastasis by inactivating Wnt/β-catenin pathway. J Cell Biochem 2017. https://doi.org/10.1002/jcb.26570 [published online ahead of print, 2017 Dec 12].

[108] Liu X, Cheng JC, Turner LS, et al. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets 2009;13(12):1449–1458. https://doi.org/10.1517/14728229.2009.3357512.

[109] Lucas JM, Heinlein C, Kim T, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Canc Discov 2014;4(11):1310–25. https://doi.org/10.1158/2159-8290.CD-13-1010.

[110] Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 2017;14(8):463–82. https://doi.org/10.1038/nrclinonc.2017.43.

[111] Luo J, Rizvi H, Egger JV, Presashag LR, Wolchok JD, Hellmann MD. Impact of PDL-1 blockade on severity of COVID-19 in patients with lung cancers. Canc Discov 2020;10(8):1121–8. https://doi.org/10.1158/2159-8290.CD-20-0596.

[112] Magruder JT, Grimm JC, Crawford TC, et al. Imatinib is protective against ischemia-reperfusion injury in an ex vivo rabbit model of lung injury. Ann Thorac Surg 2018;105(3):950–956. https://doi.org/10.1016/j.thORSUR.2017.10.002.

[113] Mao C, Yang ZY, He BF, et al. Toremifene versus tamoxifen for diagnosed multiple myeloma. Leukemia 2019;33(9):2127–2143. https://doi.org/10.1038/s41375-019-0517-6.

[114] Markham A, Keam SJ. Camrelizumab: first global approval. Drugs 2019;79(12):1355 e e 82. https://doi.org/10.1007/s41375-020-0958-y [published online ahead of print, 2020 Jul 5].

[115] Neveu G, Baronch-Bentov R, Ziv-Av A, Gerber D, Jacob Y, Einav S. Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly. PLoS Pathog 2012;8(8):e1002845. https://doi.org/10.1371/journal.ppat.1002845.

[116] Neveu G, Ziv-Av A, Baronch-Bentov R, Berkenman E, Mulholland J, Einav S. AP-2-associated protein kinase 1 and cyclin-G-associated kinase regulate hepatitis C virus entry and are potential drug targets. J Virol 2015;89(8):4387–4404. https://doi.org/10.1128/JVI.02705-14.

[117] Nguyen HS, Awad AJ, Shabani S, Doan N. Molecular targeting of acid ceramidase in glioblastoma: a review of its role, potential treatment, and challenges. Pharmaceuticals 2018;10(2):45. https://doi.org/10.3390/pharmaceutics10020045.

[118] Patel A, Sabinbien H, Clarke A, Somanath PR. Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis. Life Sci 2016:157–52. 61. https://doi.org/10.1016/j.lfs.2016.05.036.

[119] Patil NK, Guo Y, Luan L, Sherwood ER. Targeting immune cell checkpoints during sepsis. Int J Mol Sci 2017;18(11):2413. https://doi.org/10.3390/ijms18112413.

[120] Patterson B, Seethamraju H, Dhody K, et al. Disruption of the CCL5/RANTES-CCR5 pathway restores immune homeostasis and reduces plasma viral load in critical COVID-19. ResearchSquare; 2020. https://doi.org/10.21203/rs.3.rs-26517/v1.

[121] Perrone F, Piccirillo MC, Ascierto PA, et al. Tocilizumab for pa- patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial. medRxiv 2020. https://doi.org/10.1101/2020.06.01.2019149.

[122] Persson C, Silveira ER, Lemos TL, Wetmore LA, Moraes MO, Levy A. Antiproliferative effects of compounds derived from plants of Northeast Brazil. Phytother Res 2000;14(3):187–91. https://doi.org/10.1002/(sici)1099-1573(200005)14:3<187::aid-phmtr572>3.0.co;2-i.

[123] PharmaMar has submitted a Phase II clinical trial of Aplidin® (plitidepsin) for the treatment of COVID-19 to the Spanish Medicines Agency. PharmaMar 2020. Available at: http://pharmamar.com/wp-content/uploads/2020/04/PP_clinical_trial_plitidepsin_covid19_DEF.pdf. [Accessed 15 May 2020].

[124] PharmaMar reports positive results for Aplidin® against corona-virus HCoV-229E. PharmaMar 2020. Available at: http://
Phua J, Weng L, Ling L, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med 2020. https://doi.org/10.1016/S2213-2600(20)30161-2 [published online ahead of print, 2020 Apr 6] S2213-2600(20)30161-30162.

Pitman MR, Costabile M, Pitson SM. Recent advances in the development of sphingosine kinase inhibitors. Cell Signal 2020; 28(9):1349-1363. https://doi.org/10.1016/j.cellsig.2016.08.007.

Pu SY, Xiao F, Schor S, et al. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antivir Res 2018;155:67-75. https://doi.org/10.1016/j.antiviral.2018.05.001.

Pundi K, Perino AC, Harrington RA, Krumholz HM, Turakhia MP. Characteristics and strength of evidence of COVID-19 studies registered on ClinicalTrials.gov. JAMA Intern Med 2020;e202904. https://doi.org/10.1001/jamanetworkmed.2020.2904 [published online ahead of print, 2020 Jul 27].

Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019;18(7):517-558. https://doi.org/10.1038/s41573-018-0018-x.

Pyne NJ, Adams DR, Pyne S. Sphingosine kinase 2 in autoimmune/inflammatory disease and the development of sphingosine kinase 2 inhibitors. Trends Pharmacol Sci 2017;38(7):581-591. https://doi.org/10.1016/j.tips.2017.04.003.

Qian Z, Domínguez SR, Holmes KV. Role of the splice glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation. PLoS One 2013;8(10):e76479. https://doi.org/10.1371/journal.pone.0076469.

Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020. https://doi.org/10.1093/cid/ciaa248 [published online ahead of print, 2020 Mar 12] ciaa248.

Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020;21(4):571-580. https://doi.org/10.1016/S1470-2045(20)30011-5.

Qin W, Hu L, Zhang X, et al. The diverse function of PD-1/PD-L1 pathway beyond cancer. Front Immunol 2019;10:2298. https://doi.org/10.3389/fimmu.2019.02298.

Realini N, Solorzano C, Pagliuca C, et al. Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. Sci Rep 2013;3:1035. https://doi.org/10.1038/srep01035.

Reid SP, Trutsch SR, Kota K, et al. Sphingosine kinase 2 is a chikungunya virus host factor co-localized with the viral replication complex. Emerg Microb Infect 2015;4(10):e61. https://doi.org/10.1051/emc.2015.0161.

Reinecke J, Caplan S. Endocytosis and the Src family of non-receptor tyrosine kinases. Biomol Concepts 2014;5(2):143-155. https://doi.org/10.1007/s13239-014-0003-4.

Rho O, Kim DJ, Kiguchi K, Digiovanni J. Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis. Mol Carcinog 2011;50(4):264-279. https://doi.org/10.1002/mc.20665.

Richter J, Madduri D, Richard S, Chari A. Selinexor, a next generation, oral, broad-spectrum antitumor drug, in refractory multiple myeloma. Ther Adv Hematol 2020;11. https://doi.org/10.1177/20406207207903629. Published 2020 Jun 9.

Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 2020. https://doi.org/10.1038/s41586-020-2577-1 [published online ahead of print, 2020 Jul 24].

Rizzo AN, Samman S, Esquince AE, et al. Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2015;309(11):L1294—304. https://doi.org/10.1152/ajplung.00315.2015.

Rockwell S, Liu Y. Aplidin as a potential adjunct to radiation therapy: in vitro studies. Int J Radiat Biol 2010;86(1):63—70. https://doi.org/10.3109/09553009003264531.

Roskoski Jr R. Cyclin-dependent protein serine/threonine kinase inhibitors as anticaner drugs. Pharmacol Res 2019;139:471—88. https://doi.org/10.1016/j.phrs.2019.02.008.

Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antivir Res 2014;110:94—103. https://doi.org/10.1016/j.antiviral.2014.07.014.

Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Canc 2017;17(5):271—85. https://doi.org/10.1038/nrc.2017.13.

Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;1—3. https://doi.org/10.1007/s00134-020-05991-x [published online ahead of print, 2020 Mar 3] [published correction appears in Intensive Care Med. 2020 Apr 6;].

Saccomanto CQ, de Melo GR, de Freitas CS, et al. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci Rep 2017;7:40920. https://doi.org/10.1038/srep40920 [published correction appears in Sci Rep. 2017 Apr 24;7:46772] Published 2017 Jan 18.

Saini KS, Lanza C, Romano M, et al. Repurposing anticaner drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. Br J Canc 2020;1—4. https://doi.org/10.1038/s41416-020-0948-x [published online ahead of print, 2020 Jun 22].

Sakamoto J, Hamada C, Rahman M, et al. An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer. Jpn J Clin Oncol 2005; 35(9):536-544. https://doi.org/10.1038/jjco/hey147.

Schönbührl G, Raftery MJ. The PD-1/PD-L1 axis and virus infections: a delicate balance. Front Cell Infect Microbiol 2019;9:207. https://doi.org/10.3389/fcimb.2019.00207.

Schor S, Einav S. Repurposing of kinase inhibitors as broad-spectrum antiviral drugs. DNA Cell Biol 2018;37(2):63-69. https://doi.org/10.1089/dna.2017.4033.

Schwarz S, Wang K, Yu W, Sun B, Schwarz W. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antivir Res 2011;90(1):64—69. https://doi.org/10.1016/j.antiviral.2011.02.008.

Shah KP, Song H, Ye F, et al. Demographic factors associated with toxicity in patients treated with anti-programmed cell death-1 therapy. Canc Immun 2019. https://doi.org/10.1515/bmc-2014-0003.

Sharma P, Zargar-Shoshtari K, Sexton WJ. Valrubicin in refractory non-muscle invasive bladder cancer. Expert Rev Anti-cancer Ther 2015;15(12):1379—1387. https://doi.org/10.1586/14737140.2015.1115350.

Shen LW, Mao HJ, Wu YL, Tanaka Y, Zhang W. TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections. Biochimie 2017;142:1—10. https://doi.org/10.1016/j.biochi.2017.07.016.

Sheng Z, Li G, Li B, Liu Y, Wang L. Carfilzomib-containing combinations as frontline therapy for multiple myeloma: a meta-analysis of 13 trials. Eur J Haematol 2017;98(6):601-607. https://doi.org/10.1111/ejh.12783.

Shin JS, Jung E, Kim M, Baric RS, Go YY. Saracatinib inhibits Middle East respiratory syndrome-coronavirus replication in vitro. Viruses 2018;10(6):283. https://doi.org/10.3390/v10060283. Published 2018 May 24.
Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol 2013;87(23):12552–61. https://doi.org/10.1128/JVI.01890-13.

Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol 2011;85(2):873–82. https://doi.org/10.1128/JVI.02062-10.

Siddiqui HK, Mehr A, COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 2020;39(5):405–7. https://doi.org/10.1016/j.healun.2020.03.012.

Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein–serine protease TMPRSS2. J Virol 2013;87(23):12552–4. https://doi.org/10.1128/JVI.01890-13.

Song Y, Wu J, Chen X, et al. Treatment of patients with COVID-19 who develop acute respiratory distress syndrome in humans. mBio 2012;3(6).https://doi.org/10.1128/mBio.00473-12. e00473-12. Published 2012 Nov 20.

Song DD, Zhou JH, Sheng R. Regulation and function of S protein–induced fusion is blocked prior to hemifusion by Ab1 kinase inhibitors. J Gen Virol 2018;99(5):619-630. https://doi.org/10.1099/gv.0.001047.

Song Y, Zhou KS, Zou D, et al. A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol Res 2019b;25(24):7363–9. https://doi.org/10.1158/0885-4432.CCR-19-1680.

Spicka I, Ocio EM, Oakervee HE, et al. Randomized phase III study (ADMYRE) of pletalidin in combination with dexamethasone vs. dexamethasone alone in patients with relapse/refractory multiple myeloma. Ann Hematol 2019;98(9):2139-2150.https://doi.org/10.1007/s00277-019-03739-2.

Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining anti-viral and anti-inflammatory treatments. Lancet Infect Dis 2020; 20(4):400-402. https://doi.org/10.1016/S1473-3099(20)30132-8.

Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372(2):142-152. https://doi.org/10.1056/nejmoa141321.

Stevenson KA, Brun NC, Riedel C, Rosso A, Broich K, Sendorovitz T. Master protocols in clinical trials: a universal ‘Swiss Army knife?’ Lancet Oncol 2019;20(6):e336–42. https://doi.org/10.1016/S1470-2045(19)30271-2.

Sved Y, Selenoexor: first global approval. Drugs 2019;79(13):1485–94. https://doi.org/10.1007/s40265-019-01188-9.

Sved Y. Zanubrutinib: first approval. Drugs 2020;80(1):91-97. https://doi.org/10.1007/s40265-019-01252-4.

Tanaka S, Chen-Yoshikawa TF, Kajiwara M, et al. Protective effects of imatinib on ischemia/reperfusion injury in rat lung. Ann Thorac Surg 2016;102(5):1717-1724. https://doi.org/10.1016/j.athoracsur.2016.05.037.

Tatar G, Turhan K. Investigation of N Terminal domain of SARS CoV 2 nucleocapsid protein with antiviral compounds based on molecular modeling approach. Sci Open Preprint 2020. https://doi.org/10.14293/S2199-1006.1.SOR-PPPT991.v1.

Thompson MA. The return of PRO 140, a CCR5-directed mAb. Curr Opin HIV AIDS 2018;13(4):346-353. https://doi.org/10.1097/COH.0000000000000479.

Thompson PA, et al. Preclinical evaluation of eFT226, a novel, potent and selective eIF4A inhibitor with anti-tumor activity in B-cell malignancies. Blood 2017;130(Suppl 1):1530.

Tilmanis D, van Baalen C, Oh DY, Rossagol HF, Hurt AC. The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitaoxanide. Antivir Res 2017;147:142–8. https://doi.org/10.1016/j.antiviral.2017.10.002.

Tini G, Duso BA, Bellerba F, et al. Semantic and geographical analysis of COVID-19 trials reveals a fragmented clinical research landscape likely to impair informativeness. Front Med 2020;7:367. https://doi.org/10.3389/fmed.2020.00367 (Laussanne) Published 2020 Jun 29.

Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood 2020;135(21):1912-1915. https://doi.org/10.1182/blood.2020006288.

Uddin MH, Zonder JA, Azmi AS. Exportin 1 inhibition as antiviral therapy [published online ahead of print, 2020 Jun 20]. Drug Discov Today 2020. https://doi.org/10.1016/j.drudis.2020.06.014. S1359-6446(20)30239-30247.

van Boeheim S, de Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 2012;3(6).https://doi.org/10.1126/mBio.00473-12. e00473-12. Published 2012 Nov 20.

van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, et al. Position paper: rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nat Rev Urol 2017;14(12):743–52. https://doi.org/10.1038/nrurol.2017.163.

van Hemert MJ, van den Worm SH, Knoops K, Monnmaa AM, Gorbalenya AE, Snijder EJ. SARS-coronavirus replication/transcription complexes are membrane-protected and need a host factor for activity in vitro. PLoS Pathog 2008;4(5): e1000054. https://doi.org/10.1371/journal.ppat.1000054.

Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of poly- cythemia vera. N Engl J Med 2015;372(5):426–35. https://doi.org/10.1056/NEJMoa1409002.

Venugopal S, Bar-Natan M, Mascarenhas JO. JAKs to STATs: a tantalizing therapeutic target in acute myeloid leukemia. Blood Rev 2020;40:100634. https://doi.org/10.1016/j.blre.2019.100634.

Verstoskev S, Mes RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799-807. https://doi.org/10.1056/NEJMoa1110557.

Vogel CL, Johnston MA, Capers C, Braccia D. Toremifene for breast cancer: a review of 20 years of data. Clin Breast Canc 2014;14(1):1-9. https://doi.org/10.1016/j.clbc.2013.10.014.

Vogel DT, Dingli D, Cornell RF, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol 2018;36(9):859–66. https://doi.org/10.1200/JCO.2017.75.5207.

Waksman SA, Woodruff HB. Bacteriostatic and bactericidal substances produced by a soil actinomycete. Proc Soc Exp Biol Med 1940;45:609.

Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020:1-18. https://doi.org/10.1038/s41577-020-0160-2.

Walls AC, Park YJ, Tortorici MA, Wall A, Mcguire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181(2):281–92. https://doi.org/10.1016/j.cell.2020.02.058. e6.

Wang J. Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study [published online ahead of print, 2020 May 4]. J Chem Inf Model 2020;60:0c00179. https://doi.org/10.1021/acs.jcim.0c00179. acs.jcim.
[207] Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020. https://doi.org/10.1016/j.cell.2020.03.045 [published online ahead of print, 2020 Apr 7] S0092-8674(20)30338-X.

[208] Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005;437(7058):497–504. https://doi.org/10.1038/nature03987.

[209] Wolfram J, Nizzero S, Liu H, et al. A chloroquine-induced macrophage-preconditioning strategy for improved nano-delivery. Sci Rep 2017;7(1):13738. https://doi.org/10.1038/s41598-017-14221-2.

[210] Wu M, Gui H, Feng Z, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. JAMA Intern Med 2020.e200994.https://doi.org/10.1001/jamainternmed.2020.0994

[211] Xu M, Lee EM, Wen Z, et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med 2016;22(10):1101–7. https://doi.org/10.1038/nm.4184.

[212] Xi M, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020.e200994.https://doi.org/10.1001/jamainternmed.2020.0994 [published online ahead of print, 2020 mar 13].

[213] Xu W, Gui H, Feng Z, et al. KPT-330, a potent and selective CRM1 inhibitor, exhibits anti-inflammatory effects and protection against sepsis. Biochem Biophys Res Commun 2018;503(3):313–8. https://doi.org/10.1016/j.bbrc.2018.07.112.

[214] Xie L, Xu J, Sun X, et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer 2020;8(1):e000798. https://doi.org/10.1111/jtic.2020-000798.

[215] Xu W, Sun X, Wang B, Guo H. Pooled analysis of the reports of clinical trials of COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents 2020. https://doi.org/10.1016/j.ijantimicag.2020.105982 [published online ahead of print, 2020 Apr 16].

[216] Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents 2020:105982. https://doi.org/10.1016/j.ijantimicag.2020.105982 [published online ahead of print, 2020 Apr 16].

[217] Zhao Y, Ren J, Harlos K, et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 2016;535(7610):169–72. https://doi.org/10.1038/nature18615.

[218] Zhang C, Tian B. Nonclinical safety assessment of zanubrutinib: a novel irreversible BTK inhibitor. Int J Toxicol 2020a;39(3):232–240. https://doi.org/10.1177/1054852820918511.

[219] Zhang Q, Qi Z, Bo-Liu, Li CS. Programmed cell death-ligand 1 programmed death-ligand 1 blockade improves survival of animals with sepsis: a systematic review and meta-analysis. BioMed Res Int 2018;2018:1969474. https://doi.org/10.1155/2018/1969474.

[220] Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature 2020. https://doi.org/10.1038/s41586-020-2355-0 [published online ahead of print, 2020 May 20].

[221] Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents 2020:105982. https://doi.org/10.1016/j.ijantimicag.2020.105982 [published online ahead of print, 2020 Apr 16].

[222] Zhao Y, Ren J, Harlos K, et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 2016;535(7610):169–72. https://doi.org/10.1038/nature18615.

[223] Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020. https://doi.org/10.1038/s41423-020-0402-2 [published online ahead of print, 2020 Mar 19].

[224] Zhou P, Ma B, Xu S, et al. Knockdown of Burton’s tyrosine-protein kinase confers potent protection against sepsis-induced acute lung injury. Cell Biochem Biophys 2014;70(2):1265–1275. https://doi.org/10.1007/s12013-014-0050-1.

[225] Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov 2020;6:21. https://doi.org/10.1038/s41421-020-0153-3.

[226] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from Wuhan: SARS-CoV-2. Arch Med Sci 2020;16(3):519-31. https://doi.org/10.7150/ijbs.45498.

[227] Ziogas DC, Terpos E, Kastritis E, Dimopoulos MA. An over-view of the role of carfilzomib in the treatment of multiple myeloma. Expert Opin Pharmacother 2017;18(17):1883–97. https://doi.org/10.1080/14656566.2017.1404575.

[228] Nabavi SF, Habtemariam S, Clementi E, et al. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2. Arch Med Sci 2020;16(3):519–21. https://doi.org/10.5114/aoms.2020.94504.